Use of a marker set for determining the risk of developing castration-resistant prostate cancer

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
A marker set of specific substances analyzed in body fluids using NMR spectroscopy addresses the diagnostic challenges of CRPC, enhancing differentiation from non-CRPC and predicting CRPC risk with improved accuracy.

WO2025068209A1 Publication Date: 2025-04-03NUMARES

2 Cites 0 Cited by

Patent Information

Application Number: PCT/EP2024/076828
Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2023-09-25
Filing Date: 2024-09-25
Publication Date: 2025-04-03

Application Information

Patent Timeline

25 Sep 2023

Priority

25 Sep 2024

Application

PCT/EP2024/076828

03 Apr 2025

Publication

WO2025068209A1

IPC: G01N33/574

CPC: G01N2800/50; G01N2800/60; G01N33/57555

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Disease diagnosis

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

Current methods for diagnosing prostate cancer, particularly castration-resistant prostate cancer (CRPC), are inadequate due to low specificity and sensitivity, leading to misdiagnosis and limited therapeutic options.

Method used

A marker set comprising specific substances such as acetone, 5-hydroxymethyl-2-furancarboxylic acid, phenylacetylglutamine, and others, is used to distinguish CRPC from non-CRPC and predict the risk of developing CRPC by analyzing body fluids using techniques like NMR spectroscopy.

Benefits of technology

The marker set effectively differentiates CRPC from non-CRPC and predicts the risk of CRPC development with improved accuracy, as evidenced by AUC values in ROC plots, providing a valuable diagnostic tool.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The present invention relates to the use of a marker set comprising at least four substances chosen from the group consisting of acetone, 5-hydroxymethyl-2-furancarboxylic acid, phenylacetylglutamine, N-acetylglutamine, L-tyrosine, dimethylamine, L-leucine, mannitol, sucrose, cis-aconitic acid, alanine, and scyllo-inositol in an in-vitro method for distinguishing castration-resistant prostate cancer from non-castration resistant prostate cancer and / or for determining the risk of an individual to develop castration-resistant prostate cancer.

Need to check novelty before this filing date? Find Prior Art